SAN DIEGO--(BUSINESS WIRE)--Dr. Jonathan Lakey, President and Chief Scientific Officer of MicroIslet, Inc. (MIIS.OB, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, will be moderating a discussion on the future of islet cell transplantation and cellular therapies in diabetes at the Ohio State University Global Diabetes Summit. Dr. Lakey will be speaking on the “dos and don’ts” of islet cell transplantation. The conference will be held at the Hilton Columbus at Easton on December 1, with Dr. Lakey’s address scheduled to begin at 12:00 PM EST.
